Gyeongnam Pharmaceutical Incurs Evaluation Loss on Convertible Bond Derivative Financial Liabilities
[Asia Economy Reporter Minji Lee] Kyungnam Pharmaceutical announced on the 19th that it incurred an evaluation loss related to the 5th tranche of convertible bonds. The cumulative loss balance amounts to 9.2 billion KRW, which accounts for 14% of the company's equity capital.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Russian Foreign Ministry "Hopes for Visit by North Korean Foreign Minister Choe Son Hui This Year"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "This is a derivative financial instrument evaluation loss recognized in accounting due to the difference between the conversion price of the issued convertible bonds and the stock price, caused by the stock price increase as of the end of last year."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
